Margie C Zoing
Overview
Explore the profile of Margie C Zoing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park S, Vucic S, Cheah B, Lin C, Kirby A, Mann K, et al.
EBioMedicine
. 2016 Feb;
2(12):1916-22.
PMID: 26844270
Background: Abnormalities in membrane excitability and Na(+) channel function are characteristic of amyotrophic lateral sclerosis (ALS). We aimed to examine the neuroprotective potential, safety and tolerability of the Na(+) channel...
2.
Inam S, Vucic S, Brodaty N, Zoing M, Kiernan M
Amyotroph Lateral Scler
. 2010 Jun;
11(6):558-61.
PMID: 20515425
There remains a critical need to develop biomarkers of disease progression in amyotrophic lateral sclerosis (ALS). Mobility is a key determinant of disease status and quality of life. The present...
3.
Cheah B, Boland R, Brodaty N, Zoing M, Jeffery S, McKenzie D, et al.
Amyotroph Lateral Scler
. 2009 Nov;
10(5-6):384-92.
PMID: 19922129
Respiratory impairment, due to respiratory muscle weakness, is a major cause of morbidity and mortality in patients with amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). Threshold loading may strengthen the inspiratory...
4.
Zoing M, Burke D, Pamphlett R, Kiernan M
J Clin Neurosci
. 2006 Jan;
13(1):78-83.
PMID: 16410201
Riluzole is the only therapy proven in clinical trials to prolong survival in patients with motor neurone disease (MND). Prior to its listing by the Australian Pharmaceutical Benefits Advisory Scheme...